Angiotensin-converting enzyme inhibition and angiotensin II subtype-1 receptor blockade during the progression of left ventricular dysfunction: Differential effects on myocyte contractile processes

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1082-1094

  Spinale, Francis G ^a   Holzgrefe, Henry H ^b   Mukherjee, Rupak ^a   Webb, Maria L ^b   Hird, R Barry ^a   Cavallo, Martyn J ^a   Powell, James R ^b   Koster, William H ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; IRBESARTAN; RECEPTOR SUBTYPE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; MALE; NONHUMAN; PRIORITY JOURNAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIAC PACING, ARTIFICIAL; CYCLIC AMP; DOGS; FEMALE; MALE; MYOCARDIAL CONTRACTION; NOREPINEPHRINE; RECEPTORS, ADRENERGIC, BETA; RECEPTORS, ANGIOTENSIN; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031471156     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. ALLEN, I. S., COHEN, N. M., DHALLAN, R. S., GAA, S. T., LEDERER, W. J. AND ROGERS, T. B.: Angiotensin II increases spontaneous contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes insights into mechanisms. Circ. Res. 62: 524-534, 1988.
2. ANTONACCIO, M. J. AND WRIGHT, J. J.: Renin-angiotensin system, converting enzyme, and renin inhibitors. In Cardiovascular Pharmacology, ed. by M. Antonaccio, pp. 201-228, Raven Press, New York, 1990.
3. ARMSTRONG, P. W., STOPPS, T. P., FORD, S. E. AND DEBOLD, A. J.: Rapid ventricular pacing in the dog: Pathophysiologic studies of heart failure. Circulation 74: 1075-1084, 1986.
4. BAKER, K. M., BOOZ, G. W. AND DOSTAL, D. E.: Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu. Rev. Physiol. 54: 227-241, 1992.
5. BAKER, K. M. AND SINGER, H. A.: Identification and characterization of guinea pig angiotensin II: Ventricular and atrial receptors: Coupling to inositol phosphate production. Circ. Res. 62: 896-904, 1988.
6. BENEDICT, C. R., WEINER, D. H., JOHNSTONE, D. E., BOURASSA, M. G., GHALI, J. K., NICKLAS, J., KIRLIN, P., GREENBERG, B., QUINONES, M. A. AND YUSUF, S.: The SOLVD investigators.: Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction. Results of the studies of left ventricular dysfunction (SOLVD) registry. J. Am. Coll. Cardiol. 22: 146A-153A, 1993.
7. BIENVENU, J. G. AND DROLET, R.: A quantitative study of cardiac ventricular mass in dogs. Can. J. Vet. Res. 55: 305-309, 1991.
8. BRISTOW, M. R., GINSBURG, R., UMANS, V., FOWLER, M., MINOBE, W., RASMUSSEN, R., ZERA, P., MENLOVE, R., SHAH, P., JAMIESON, S. AND STINSON, E. B.: β1 and β2 Adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium coupling of both receptor subtypes to muscle contraction and selective β1-receptor down regulation in heart failure. Circ. Res. 59: 297-309, 1986.
9. CAZAUBON, C., GOUGAT, J., BOUSQUET, F., GURAUDOU, P., GAYRAUD, R., LACOUR, C., ROCCON, A., GALINDO, G., BARTHELEMY, G., GAUTRET, B., BERNHART, C., PERREAUT, P., BRELIERE, J-C., LEFUR, G. AND NISATO, D.: Pharmacological characterization of SR 47436, a new nonpeptide ATI subtype angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther. 265: 826-265, 1993.
10. CORY, R. C., MCCUTCHEON, L. J., OGRADY, M., PANG, A. W., GEIGER, J. D. AND OBRIEN, P. J.: Compensatory down-regulation of myocardial Ca channel in SR from dogs with heart failure. Am. J. Physiol. 264: H926-H937, 1993.
11. DUDLEY, D. T., PANEK, R. L., MAJOR, T. C., LU, G. H., BRUNS, R. F., KLINKEFUS, B. A., HODGES, J. C. AND WIESHAAR, R. E.: Subclasses of angiotensin II binding sites and their functional significance. Mol. Pharmacol. 38: 370-377, 1990.
12. DZAU, V. J.: Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 77: suppl. I, 14-113, 1988,
13. EBLE, D. M. AND SPINALE, F. G.: Effects of chronic supraventricular tachycardia on contractile and non-contractile mRNA expression: relation to changes in myocyte structure and function. Am. J. Physiol. 268: H2426-H2439, 1995.
14. EHRING, T., BAUMGART, D., KRAJCAR, M., MUMMELGEN, M., KOMPA, S. AND HEUSCH, G.: Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation 90: 1368-1385, 1994.
15. αi-2 in human end stage heart failure. Circ. Res. 70: 688-696, 1992.
16. FINCKH, M., HELLMANN, W., GANTEN, D., FURTWANGLER, A., ALLGEIER, J., BOLTZ, M. AND HOLTZ, J.: Enhanced cardiac angiotensinogen gene expression and angiotensin converting enzyme activity in tachypacing induced heart failure in rats. Basic Res. Cardiol. 86: 303-316, 1991.
17. GAVRAS, H.: Angiotensin converting enzyme inhibition and the heart. Hypertension 23: 813-818, 1994.
18. GOHLKE, P., LINZ, W., SCHOLKENS, B. A., KUWER, I., BARTENBACH, S., SCHNELL, A. AND UNGER, T.: Angiotensin converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 23: 411-418, 1994.
19. GOLDSTEIN, D. S., FEUERSTEIN, G., IZZO, H. L., KOPIN, I. J. AND KEISER, H.: Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci. 83: 265-269, 1986.
20. HIRSCH, A. T., TALSNESS, C. E., SCHUNKERT, H., PAUL, M. AND DZAU, V. J.: Tissue specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ. Res. 69: 475-482, 1991.
21. +-ATPase α-subunit in congestive heart failure. Role of norepinephrine. Circulation 89: 313-320, 1994.
22. LAURENCEAU, J. L. AND MALERGUE, M. C.: The Essentials in Echocardiography, M-mode and 2-Dimensional Imaging, pp. 64-70, Martinus Nijhoff, Boston, MA, 1981.
23. LEVENS, N. R., GASPARO, M., WOOD, J. M. AND BOTTARI, W. P.: Could the pharmacological differences observed between angiotensin II antagonists and inhibitors of angiotensin converting enzyme be clinically beneficial? Pharmacol. Toxicol. 71: 241-249, 1992.
24. LINDPAINTNER, K. AND GANTEN, D.: The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ. Res. 68: 905-921, 1991.
25. LOPEZ, J. J., LORELL, B. H., INGELFINGER, J. R., WIENBERG, E. O., SCHUNKERT, H., DIAMANT, D. AND TANG, S. S.: Distribution and function of cardiac AT1 and AT2 receptor subtypes in hypertrophied rat hearts. Am. J. Physiol. 267: H844-H852, 1994.
26. MAISEL, A. S., PHILLIPS, C., MICHEL, M. C., ZIEGLER, M. G. AND CARTER, S. M.: Regulation of cardiac β-adrenergic receptors by captopril. Implications for congestive heart failure. Circulation 80: 669-675, 1989.
27. MARGULIES, K. B., HEUBLEIN, D. M., PERRELLA, M. A. AND BURNETT, J. C.: ANF-mediated renal cGMP generation in congestive heart failure. Am. J. Physiol. 260: F562-F568, 1991.
28. MCDONALD, K. M., GARR, M., CARLYLE, P. F., FRANCIS, G. S., HAUER, K., HUNTER, D. W., PARISH, T., STILLMAN, A. AND COHN, J. N.: Relative effects of α1 adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 90: 3034-3046, 1994.
29. MCDONALD, K. M., MOCK, J., D'ALOIA, A., PARRISH, T., HAUER, K., FRANCIS, G., STILLMAN, A. AND COHN, J. N.: Bradykinin antagonism inhibits the anti-growth effects of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 91: 2043-2048, 1995.
30. MUKHERJEE, R., HEWETT, K. W., CRAWFORD, F. A. AND SPINALE, F. G.: Cell and sarcomere contractile properties from the same cardiocyte. J. Appl. Physiol, 74: 2023-2033, 1993.
31. NOLLY, H., CARBINI, L. A., SCICLI, G., CARRETERO, O. A. AND SCICLI, G.: A local kallikrein-kinin system is present in rat hearts. Hypertension 23: 919-923, 1994.
32. PERREAULT, C. L., SHANNON, R. P., KOMAMURA, K., VATNER, S. F. AND MORGAN, J. P.: Abnormalities in intracellular calcium regulation and contractile function in myocardium from dogs with pacing induced heart failure. J. Clin. Invest. 89: 932-938, 1992.
33. PING, P. AND HAMMOND, K. H.: Diverse G protein and β-adrenergic receptor mRNA expression in normal and failing porcine hearts. Am. J. Physiol. 267: H2079-H2085, 1994.
34. ROTH, D. A., KAZUSHI, U., HELMER, G. A. AND HAMMOND, H. K.: Downregulation of cardiac guanosine 5′-triphosphate binding proteins in right and left ventricle in pacing induced congestive heart failure. J. Clin. Invest. 91: 939-949, 1993.
35. SABBAH, H. N., SHIMOYAMA, H., KONO, T., GUPTA, R. C., SHAROV, V. G., SCICLI, G., LEVINE, T. B. AND GOLDSTEIN, S.: Effects of long term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 89: 2852-2859, 1994.
36. SCHUNKERT, H., JACKSON, B., TANG, S. S., SCHOEN, F. J., SMITS, J. F. M., APSTEIN, C. S. AND LORELL, B. H.: Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 87: 1328-1339, 1993.
37. SECHI, L. A., GRIFFIN, C. A., GRADY, E. F., KALINYAK, J. E. AND SCHAMBELAN, M.: Characterization of angiotensin II receptor subtypes in rat heart. Circ. Res. 71: 1482-1489, 1992.
38. +-ATPase in tachycardia induced cardiomyopathy. J. Mol. Cell. Cardiol. 24: 277-294, 1992a.
39. SPINALE, F. G., FULBRIGHT, B. M., MUKHERJEE, R., TANAKA, R., HU, J., CRAWFORD, F. A. AND ZILE, M. R.: Relationship between ventricular and myocyte function with tachycardia induced cardiomyopathy. Circ. Res. 71: 174-187, 1992b.
40. SPINALE, F. G., HENDRICK, D. A., CRAWFORD, F. A., SMITH, A. C., HAMADA, Y. AND CARABELLO, B. A.: Chronic supraventricular tachycardia causes ventricular dysfunction and subendocardial injury in swine. Am. J. Physiol. 259: H218-H229, 1990.
41. SPINALE, F. G., HOLZGREFE, H. H., MUKHERJEE, R., HIRD, R. B., WALKER, J. D., ARNIM-BARKER, A., POWELL, J. R. AND KOSTER, W. H.: Angiotensin converting enzyme inhibition and the progression of congestive cardiomyopathy: Effects on left ventricular and myocyte structure and function. Circulation 92: 562-568, 1995.
42. SPINALE, F. G., TEMPEL, G. E., MUKHERJEE, R., EBLE, D. M., BROWN, R., VACCHIANO, C. AND ZILE, M. R.: Cellular and molecular changes in the β-adrenergic receptor system with supraventricular tachycardia induced cardiomyopathy. Cardiovasc. Res. 28: 1243-1250, 1994.
43. STEEL, R. G. D. AND TORRIE, J. H.: Principles and Procedures of Statistics: A Biometrical Approach, 2nd ed., pp. 1-623, McGraw-Hill, New York, 1980.
44. THE CONCENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandanavian Enalapril Survival Study (CONCENSUS). N. Engl. J. Med. 316: 1429-1435, 1987.
45. THE SOLVD INVESTIGATORS: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325: 293-302, 1991.
46. TOMITA, M., SPINALE, F. G., CRAWFORD, F. A. AND ZILE, M. R.: Changes in left ventricular volume, mass and function during development and regression of supraventricular tachycardia induced cardiomyopathy: disparity between recovery of systolic vs diastolic function. Circulation 83: 635-644, 1991.
47. TRAVILL, C. M., WILLIAMS, T. D. M., PATE, P., SONG, G., CHALMERS, J., LIGHTMAN, S. L., SUTTON, R. AND NOBLE, M. I. M.: Hemodynamic and neurohormonal response in heart failure produced by rapid ventricular pacing. Cardiovasc. Res. 26: 783-790, 1992.
48. URATA, H., BOEHM, K. D., PHILIP, A., KINOSHITA, A., GABROVSEK, J., BUMPUS, F. M. AND HUSAIN, A.: Cellular localization and regional distribution of an angiotensin II forming chymase in the heart. J. Clin. Invest. 91: 1269-1281, 1993.
49. URATA, H., HEALY, B., STEWART, R. W., BUMPUS, F. M. AND HUSAIN, A.: Angiotensin II receptors in normal and failing human hearts. J. Clin. Endocrinol. Metab. 69: 54-66, 1989.
50. URATA, H., HEALY, B., STEWART, R. W., BUMPUS, F. M. AND HUSAIN, A.: Angiotensin II forming pathways in normal and failing human hearts. Circ. Res. 66: 883-890, 1990.
51. VAN DEN MEIRACKER, A. H., ADMIRAAL, P. J. J., JANSSEN, J. A., KROODSMA, J. M., DE RONDE, W. A. M., BOOMSMA, F., SISSMANN, J., BLANKESTIJN, P. J., MULDER, P. G. M., MAN IN 'T VELD, A. J. AND SCHALEKAMP, M. A. D. H.: Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension 25: 22-29, 1995.
52. WEBER, K. T., SUN, Y. AND GUARDA, E.: Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 23: 869-877, 1994.
53. WILLIAMS, R. E., KASS, D. A., KAWOGOE, Y., PAK, P., TUNIN, R. S., SHAH, R., HWANG, A. AND FELDMAN, A. M.: Endomyocardial gene expression during development of pacing tachycardia induced heart failure in the dog. Circ. Res. 75: 615-623, 1994.
54. ZILE, M. R., TANAKA, R., LINDROTH, J. R., SPINALE, F. G., CARABELLO, B. A. AND MIRSKY, L: Left ventricular volume determined echocardiographically by using a constant LV epicardial long axis to short axis dimension ratio throughout the cardiac cycle. J. Am. Coll. Cardiol. 20: 986-983, 1992.